Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIANT: Nivolumab and Relatlimab in Newly Diagnosed Glioblastoma
NCT06816927Phase 2Recruiting
- Sponsor
- Duke University
- Start
- Nov 2025
- Primary completion
- Jun 2029
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Nivolumab with Nivolumab and Relatlimab (2 arms). Primary endpoints: Safety of concomitantly administering nivolumab, relatlimab, RT, and TMZ at 4 weeks, Feasibility of peri-operative study at 4 weeks and 1 more. Started Nov 2025; status: recruiting.
02
Drugs
nivolumabrelatlimab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06816927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06816927.